source
- Osivax licenses GC Biopharma seasonal flu vaccine to develop combined OVX836-GC FLU shotOsivax has secured a non-exclusive license from GC Biopharma for its seasonal influenza vaccine, GC FLU, to pair with Osivax’s mid-phase candidate OVX836. OVX836 targets the conserved nucleoprotei…
- Akeso CEO says biliary tract cancer data could be a breakthroughAkeso’s chief executive Michelle Xia told ChinaPharma that the company’s PD-1xVEGF bispecific antibody, ivonescimab, is generating strong interest after early biliary tract cancer results. She not…